AFRICAN UNION





UNION AFRICAINE

UNIÃO AFRICANA

Addis Ababa, ETHIOPIA

P. O. Box 3243

Telephone: 011-551 7700

Fax: 011-551 7844

website: www. africa-union.org

SECOND SESSION OF THE SPECIALISED TECHNICAL COMMITTEE ON HEALTH, POPULATION AND DRUG CONTROL (STC-HPDC-2) ADDIS ABABA, ETHIOPIA 20-24 MARCH 2017

Theme: "Youth, Health and Development: Overcoming the Challenges towards Harnessing the Demographic Dividend"

ADDIS ABABA COMMITMENT ON THE ESTABLISHMENT OF A FUND FOR AFRICAN PHARMACEUTICAL SECTOR DEVELOPMENT (FAP-D)

ADDIS ABABA COMMITMENT ON THE ESTABLISHMENT OF A FUND FOR AFRICAN PHARMACEUTICAL SECTOR DEVELOPMENT (FAP-D)

We members of the AU Specialized Technical Committee on Health, Population and Drug Control, having met at our 2nd ordinary session in Addis Ababa, Ethiopia, from 23-24 March 2017, on the theme 'Youth, *Health and Development: Overcoming the challenges towards Harnessing the Demographic Dividend*' and having deliberated on the proposal for the establishment of a fund for local African pharmaceutical sector development as a critical input in accelerating the achievement of the objectives of the Pharmaceutical Manufacturing Plan for Africa (PMPA);

Recalling Assembly Decision 55 {Assembly /AU/Dec.55 (IV)} of June 2005, that recognized the need for ensuring medicines security on the continent and Assembly Decision {Assembly AU/Dec.442 (XIX)} of January 2012 which endorsed the PMPA business plan that envisions the development of a competitive local pharmaceutical industry in Africa to ensure self-reliance in rapidly responding to public healthcare needs for access to essential, quality, safe and effective medical products and technologies;

Desirous of the benefits of knowledge, skills, innovation and technology based economies created by a competitive local pharmaceutical industry and the potential to create jobs for the youth in the sector and other linked industries and thereby contribute to harnessing Africa's demographic dividend;

Acknowledging the current efforts being made by local pharmaceutical companies to attain Good Manufacturing Practices (GMP) standards and the commitment by some Member States to implement various forms of time-limited incentives and the potential this has for the emergence of a sustainable and competitive local industry contributing to social and economic transformation and inclusive growth trajectory enshrined in AU Agenda 2063 and the Sustainable Development Goals. (SDGs)

We hereby:

Reaffirm our commitment to promoting a secure and reliable supply of essential medicines, vaccines, diagnostics, technologies and health commodities as critical in strengthening and securing Africa's health systems;

Commit to increase and prioritize innovative procurement of medical products manufactured within Africa and to participate in the design and implementation of other forms of incentives to accelerate attainment of the PMPA objectives;

Request the Commission to seek support of the Specialized Technical Committee (STC) on Finance, Monetary Affairs, Economic planning and Integration; and the STC on Trade, Minerals and Industry for the establishment, funding and implementation of FAP-D;